Help - Search - Members - Calendar
Full Version: Community
Positively Aware > The PA Lounge > Community
Pages: 1, 2, 3, 4, 5, 6
  1. Pinned: How to use this forum (0 replies)
  2. RIP - Robert Navarret (0 replies)
  3. RIP Pete Jimenez – 02/12/64 04/13/12 (0 replies)
  4. New Guidelines: Anti-Seizure Drug Selection for People Living With HIV (0 replies)
  5. New Studies Under Way of Sangamo's Possible 'Functional Cure' Gene Therapy (0 replies)
  6. Experts Issue Early Guide for Hep C Protease Inhibitor Therapy in People Living with HIV (0 replies)
  7. Chronic Hep B Doubles Risk of AIDS Illnesses and Death in People Living With HIV (0 replies)
  8. Improper Use of a Neti Pot Can Be Fatal (0 replies)
  9. Rituxan Prolongs HIV-Related Lymphoma Survival (0 replies)
  10. December 15 Webinar on Sequestration Effects on HIV Programs (0 replies)
  11. Headache Affects One of Every Two HIV/AIDS Patients (0 replies)
  12. Activists Launch New Survey, Ask People With HIV to Take 10 minutes to Help Speed HIV Cure Research (0 replies)
  13. Milk Thistle Extract Comparable to Placebo in Hep C Liver Enzyme Study (0 replies)
  14. Complete One-Pill, Once-Daily Prezista-Based HIV Regimen Enters Development (0 replies)
  15. Blood Thinner Reduces Liver Vein Blood Clots, Protects Liver Functioning in People With Cirrhosis (0 replies)
  16. U.S. Supreme Court to Hear Challenge to Health Care Reform (0 replies)
  17. FDA Warns of Serious Skin Reactions Among Isentress Users (0 replies)
  18. Low Levels of HIV in the Blood Aren’t Connected to Inflammation or Death (0 replies)
  19. Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype (0 replies)
  20. New Technologies May Increase Adherence to HIV Drugs (0 replies)
  21. Bristol-Myers, Gilead Work on New Combo HIV Pill (0 replies)
  22. Janssen Announces FDA Label Update Approval for PREZISTA HIV Tablets (0 replies)
  23. Complera Receives "Alternative" U.S. Treatment Guidelines Status (0 replies)
  24. Life Expectancy at All-Time High in U.K. Cohort Study (0 replies)
  25. Death Rates Among People With HIV Vary Considerably From State to State, CDC Reports (0 replies)
  26. UCLA Researchers Find Gene Therapy That Can Prevent Cells From HIV Infection (0 replies)
  27. Cohort Study: No AIDS-Free Survival Benefit to Starting HIV Treatment at CD4s of 500 or More (0 replies)
  28. Waist and Triglyceride Measurements Help Gauge Cardiovascular Disease Risk in HIV (0 replies)
  29. Overweight Patients Have Best Gains in CD4 Cell Count Twelve Months After Starting HIV Therapy (0 replies)
  30. Distinct AIDS Viruses Found in Cerebrospinal Fluid of People with HIV Dementia (0 replies)
  31. ACTION ALERT - Call Congress BEFORE October 13th to Protect Ryan White and Other HIV Programs in the Deficit Reduction Package! (0 replies)
  32. HIV Antibody Therapy Ibalizumab Inches Forward (0 replies)
  33. Promising Results from MVA-B HIV Vaccine Trial (0 replies)
  34. Gilead: Second Trial of 4-Drug AIDS Pill Meets Goal (0 replies)
  35. Big Falls in Prevalence of Protease Inhibitor and Triple-class Resistance (0 replies)
  36. A Fifth of Patients Discontinue Atripla Within a Year, CNS Side-effects The Main Reason (0 replies)
  37. HIV Neuropathy Pain Patch Reaches for FDA Approval (0 replies)
  38. Fluctuating Symptoms Have A Major Impact On The Lives Of Many People With HIV (0 replies)
  39. The Levels of Viral Load in Blood and Rectal Secretions Are Related (0 replies)
  40. Hepatitis E Could Be A Cause Of Unexplained Changes In Liver Function In People Living With HIV. (0 replies)
  41. TB – Development After Starting HIV Treatment (0 replies)
  42. Dual Syphilis-HIV Cases on Rise in Cleveland, County: New Syphilis Diagnoses Mostly Men Under 35 (0 replies)
  43. US Research Suggests That Many HIV-positive Men Who Have Sex With Men Are Abused By Their Partners (0 replies)
  44. Data from University of Alabama Advance Knowledge in HAART (0 replies)
  45. videos of HIV talks/lectures/trainings (0 replies)
  46. Cobicistat Comparable to Norvir as HIV Boosting Agent (0 replies)
  47. Statins Greatly Reduce Risk of Death in HIV Cohort Study (0 replies)
  48. Doubled Risk of Death Among Publicly Insured People With HIV in U.S. (0 replies)
  49. AIDS Drugs Can Cause Premature Aging: Study (0 replies)
  50. Flagship Research is Looking for People Diagnosed with HIV for a Paid Study (0 replies)
  51. National Prevention Strategy Released (0 replies)
  52. National Museum of American History Marks 30th Anniversary of HIV and AIDS (0 replies)
  53. UNAIDS Releases latest HIV/AIDS Statistics (0 replies)
  54. The 30 Years War: AIDS, a Tale of Tragedy and Hope (0 replies)
  55. New Push Aims to Find Cure for AIDS Virus (0 replies)
  56. We Will 'Ultimately End' AIDS: US Researcher (0 replies)
  57. Early Drug Treatment Greatly Cuts Spread of HIV (0 replies)
  58. Merck's Hepatitis C Drug Wins FDA Approval (0 replies)
  59. Utah Closes Free HIV Medication Program to New Patients (0 replies)
  60. FDA Panel Backs Experimental Merck Hepatitis Drug (0 replies)
  61. Moving Can Be Hazardous to the Health for HIV Positive People (0 replies)
  62. Anti-CMV Drug Reduces HIV-Related Inflammation (0 replies)
  63. Some Cancers of the Stomach and Esophagus Are More Common in People With AIDS (0 replies)
  64. Brain Impairment Might Be Less Common in People With HIV Than Originally Suspected (0 replies)
  65. Tenofovir Might Reduce Inflammation, Boost Immune System (0 replies)
  66. Peripheral Nerve Damage Remains Common Despite HIV (0 replies)
  67. Could Switching HIV Therapy Early Avoid Treatment Failure? (0 replies)
  68. ACTION ALERT - National Call–in Day to Support Funding for Domestic HIV/AIDS Programs is April 5th. (0 replies)
  69. New EEOC Regulations Include HIV as a Disability (0 replies)
  70. New Viramune Tablet Approved for Once-Daily Use (0 replies)
  71. Cellular Proteins Responsible For Viral Replication Identified To Help Develop New Therapeutics For HIV/AIDS (0 replies)
  72. Reyataz May Be Safe for HIV-Positive People With Severe Liver Disease (0 replies)
  73. Another Study Finds No Heart Attack Risk From Abacavir (0 replies)
  74. Pooled Trial Results Suggest Capsaicin Patch Relieves Neuropathy (0 replies)
  75. Vertex Drug Promising in Hepatitis C Patients with HIV (0 replies)
  76. CD4s, Viral Load Not Enough to Predict Survival During HIV Treatment (0 replies)
  77. Non-AIDS-Related Cancers Are Now the Leading Cause (0 replies)
  78. HIV Non-Nuke Rilpivirine Less Likely Than Sustiva to (0 replies)
  79. Bone Loss During HIV Treatment: A Possible Side Effect of CD4 Cell Recovery (0 replies)
  80. Study Says HIV and Inflammation, Not ARVs, Predict Cardiovascular Risk (0 replies)
  81. Muscle Loss, Fat Gain Associated With Increased Risk of Death (0 replies)
  82. Previous Syphilis Infection Might Cause Poorer Brain Function for People With HIV (0 replies)
  83. Many HIV Patients Carry Strain With Drug-Resistant (0 replies)
  84. Submit Comments to HUD about HOPWA in Your Community (0 replies)
  85. Early Registration Now Open for NORTH AMERICAN HOUSING & HIV/AIDS RESEARCH SUMMIT VI (0 replies)
  86. Other Routes to HIV Drug Assistance (0 replies)
  87. AIDS Activists Call on Public to Support New FDA HIV Drug Approval Policy (0 replies)
  88. Equal Access to Housing in HUD Programs Regardless of Sexual Orientation or Gender Identity (0 replies)
  89. ACTION ALERT - Urge Congress Not to Cut the Ryan White Program This Year! (0 replies)
  90. Florida Sidesteps AIDS Drug Crisis for Now (0 replies)
  91. 'Smart Bomb' RNA Molecule Could Take Out Drug-Resistant (0 replies)
  92. HIV Lipo Drug Egrifta Now Available; Financial Assistance Programs Open (0 replies)
  93. AIDS Drug Assistance Program Activists Schedule 'Crisis' Summit to Find Solutions for Budget Hole (0 replies)
  94. Stroke Rates Increasing in People With HIV (0 replies)
  95. Funding Gap Threatens Florida AIDS Drug Help (0 replies)
  96. ACTION ALERT - Tell Congress To Oppose Repeal of Health Care Reform (0 replies)
  97. GOP Legislator Wants to Cut Off HIV Funding (0 replies)
  98. Museum of Modern Art to Display Controversial Video (0 replies)
  99. GeoVax Labs Expands Phase 2a Human HIV/AIDS Vaccine Trial (0 replies)
  100. UF Researchers Receive $4.7 Million to Study Ties Between Marijuana Use and HIV Infection (0 replies)
  101. Undetectable Viral Load Key to Long-Term Health in Late HIV Treatment Starters (0 replies)
  102. Lipitor and Crestor Are Better Than Pravachol for HIV Treatment-Related Cholesterol Problems (0 replies)
  103. Age-Related Declines in Physical Function No More Common in HIV (0 replies)
  104. U.S. Government Updates HIV Treatment Guidelines (0 replies)
  105. New Study in San Francisco Aims to Improve HIV Care for Aging Population (0 replies)
  106. HIV Super-Infection Beliefs and Sexual Practices of People Living with HIV/AIDS (0 replies)
  107. Hope Survives: 30 Years of AIDS will Air Friday, January 14th at 9pm ET (0 replies)
  108. Vitamin D Deficiencies Linked to Diabetes in People With HIV (0 replies)
  109. Virginia to Move 760 ADAP Clients to Waiting List (0 replies)
  110. FDA Approves Gardasil Vaccine For Prevention Of Anal Cancer (0 replies)
  111. New HIV Treatment Found (0 replies)
  112. HIV Drug & Alcohol Task Force (0 replies)
  113. Season's Greetings! (0 replies)
  114. New York HIV/AIDS Agency Seeks Clients for Nutrition Program (0 replies)
  115. Delaying Treatment for HIV Can Become Costly (0 replies)
  116. Press Conference, Rally Planned to Address Georgia's AIDS Drug Waiting List (0 replies)
  117. Egrifta Gets FDA Approval for HIV-Associated Lipodystrophy (0 replies)
  118. Bone Loss More Common in HIV (0 replies)
  119. Florida to Drop 350 Patients in AIDS Drug Program (0 replies)
  120. Longer Hep C Treatment Improves Response in People Coinfected With HIV (0 replies)
  121. Liver Cancer Survival Similar in HIV-Positive and HIV-Negative People (0 replies)
  122. FDA Warns of Heart Risk with HIV Drug Combination (0 replies)
  123. Smoking-Related Health Risks Among Persons with HIV in the Strategies for Management of Antiretroviral Therapy Clinical Trial (0 replies)
  124. Amgen Issues Partial Recall of Epogen and Procrit (0 replies)
  125. Pelosi Supports $75 Million for ADAP (0 replies)
  126. Program Offers Free HIV Drugs for ADAP Waitlisted (0 replies)
  127. S.C. Prisons Brace for Lawsuit over Inmates with HIV (0 replies)
  128. HIV Said to Differ in Blood, Semen (0 replies)
  129. Florida HIV Patients Getting Help from Pharmaceutical Companies (0 replies)
  130. Working Group Develops Recommendations for NHAS Operational Plans (0 replies)
  131. Latino Leaders Call for Increased AIDS Awareness / Enhanced Resources to Combat HIV Epidemic in Their Communities (0 replies)
  132. Spectrum of Cancer Risk Late After AIDS Onset in the United States (0 replies)
  133. AIDS Patients in Florida Have Longest Wait to Get Assistance for Drug Programs (0 replies)
  134. Florida Health Care Conference Targets HIV/AIDS (0 replies)
  135. EditCalling All Artists - POSITIVE INSPIRATIONS Wants You! (0 replies)
  136. Calling All Photographers - POSITIVE INSPIRATIONS Wants You! (0 replies)
  137. Calling All Poets - POSITIVE INSPIRATIONS Wants You! (0 replies)
  138. Ohio State Funds Mix-Up Delays HIV Drug Payments (0 replies)
  139. CDC Funds Bay Area Collaborative to Deliver HIV Prevention to Asians and Pacific Islanders (0 replies)
  140. Obama Seeks Boosts in Funds for AIDS Prevention, Research (0 replies)
  141. Two Approved Cancer Drugs Fight HIV (0 replies)
  142. Wisconsin AIDS Resource Center Expands Services (0 replies)
  143. Global Survey: Stigma, Isolation and Discrimination Still Pervasive (0 replies)
  144. ACTION ALERT - Tell Bristol-Myers Squibb to Lower the Price of Reyataz (0 replies)
  145. HOPWA Receives $5 Million Increase from FY2010 Level (0 replies)
  146. The International AIDS Housing Roundtable Releases Report (0 replies)
  147. ACTION ALERT - Urge T-HUD Subcommittee to Approve $410 for HOPWA! (0 replies)
  148. Great resource for for case managers & other front-line staff (0 replies)
  149. Support The Vienna Declaration! (0 replies)
  150. White House to Unveil The National HIV/AIDS Strategy (0 replies)
This is a "lo-fi" version of our main content. To view the full version with more information, formatting and images, please click here.
Invision Power Board © 2001-2013 Invision Power Services, Inc.